Dotinurad

ApprovedSmall molecule

Eisai

Dotinurad is one of 52 small molecule programs targeting Hyperuricemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperuricemiaActive, not recruiting

GoutNot yet recruiting

HyperuricemiaApproved

Active, not recruiting

GoutApproved

Not yet recruiting

Competition

Competitive Landscape

47 competitors in Hyperuricemia

#DrugCompanyPhaseTrials

Uloric

Takeda

Approved

12 2

Medrol

Farxiga

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 5

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

1 6

Decadron

AAspen Global Incorporated

Approved

—7

Zyloprim

Alnylam Pharmaceuticals

Phase 2

4 8

Colcrys

Alnylam Pharmaceuticals

Phase 2

3 9

Dotinurad

Eisai

Approved

1 10

Febuxostat Tab

XXuhui Central Hospital, Shanghai

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedNot yet recruiting

Gout

NCT07661030

Q4 2027

Phase 3Recruiting

Gout

NCT07089875

Phase 3Recruiting

Tophaceous Gout

NCT07089888

Q1 2030

Post-ApprovalRecruiting

Hyperuricemia

NCT06834230

Clinical

Trials by Indication[1]

Gout2 trials

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Recruiting·CCrystalys Therapeutics·Phase 3·NCT07089875·500 enrolled

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Approved·NCT07661030·142 enrolled

Tophaceous Gout1 trial

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Recruiting·CCrystalys Therapeutics·Phase 3·NCT07089888·250 enrolled

ART1 trial

A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants

Completed· Eisai logo

Eisai·Phase 1·NCT05278676·26 enrolled

Treatment1 trial

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Completed· Eisai logo

Eisai·Phase 3·NCT05007392·451 enrolled

Hyperuricemia1 trial

Effect of Dotinurad in Hyperuricemia With Hypertension

Recruiting·—·Phase 4·NCT06834230·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Dotinurad. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dotinurad compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dotinurad. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

Dotinurad

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2030

Trials by Indication[1]

Gout2 trials

Tophaceous Gout1 trial

ART1 trial

Treatment1 trial

Hyperuricemia1 trial

References

Drug Info

Quick Facts

Related News